The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

Published:2020-01-01 Issue:1 Volume:6 Page:116
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Sledge George W.¹,Toi Masakazu²,Neven Patrick³,Sohn Joohyuk⁴,Inoue Kenichi⁵,Pivot Xavier⁶,Burdaeva Olga⁷,Okera Meena⁸,Masuda Norikazu⁹,Kaufman Peter A.¹⁰,Koh Han¹¹,Grischke Eva-Maria¹²,Conte PierFranco¹³,Lu Yi¹⁴,Barriga Susana¹⁵,Hurt Karla¹⁴,Frenzel Martin¹⁴,Johnston Stephen¹⁶,Llombart-Cussac Antonio¹⁷

Affiliation:

1. Stanford University School of Medicine, Stanford, California

2. Graduate School of Medicine, Kyoto University, Kyoto, Japan

3. Universitaire Ziekenhuizen Leuven, Leuven, Belgium

4. Yonsei Cancer Center, Seoul, Korea

5. Saitama Cancer Center, Saitama, Japan

6. Centre Paul Strauss, INSERM 110, Strasbourg, France

7. Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russia

8. Adelaide Cancer Centre, Adelaide, Australia

9. National Hospital Organization, Osaka National Hospital, Osaka, Japan

10. University of Vermont Cancer Center, Burlington

11. Kaiser Permanente, Bellflower, California

12. Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany

13. DiSCOG, University of Padova and Medical Oncology 2, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy

14. Eli Lilly and Company, Indianapolis, Indiana

15. Eli Lilly and Company, Madrid, Spain

16. The Royal Marsden NHS Foundation Trust, London, United Kingdom

17. Hospital Arnau Vilanova, Valencia, Spain

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2752266/jamaoncology_sledge_2019_oi_190093.pdf

Reference23 articles.

1. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy.;Sledge;J Clin Oncol,2017